November 22, 2023
A Community Update on AbbVie’s HIV Cure Research Program
Webinar / Presentation
On Tuesday, December 5, 2023 at 12 pm (ET) Join us for an update on HIV cure-related research studies being conducted by the company AbbVie…

November 16, 2023
Submission on the Right to Access and Take Part in Scientific Progress
Letter / Comment
TAG is a longstanding champion of the human right to science, which we believe entitles everyone, everywhere to benefit from the best available tools to end HIV, TB, and HCV.

November 15, 2023
Research Toward a Cure Trials
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

November 9, 2023
An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis
Publication
In 2022, the World Health Organization (WHO) updated its guidelines for treating drug-resistant tuberculosis (DR-TB), recommending a six-month cure. This guide lays out what activists need to know about the new DR-TB treatment regimens, including an overview of findings from the trials that underpin the updated WHO guidelines and important…

November 7, 2023
ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS
Statement / Press
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of…

November 6, 2023
Treatment Action Group Calls for Immediate Ceasefire in Gaza to Protect Health and Lives
Statement / Press
Treatment Action Group (TAG) urgently calls for an immediate ceasefire in Gaza. We grieve Israeli and Palestinian lives lost before, on, and since October 7, and unequivocally condemn the Hamas attacks that killed more than 1,400 Israelis, including some 30 children.

October 16, 2023
Treatment Action Group Resource on the Demographics of Participation in HIV Cure-Related Clinical Research
In 2014, TAG began tracking HIV cure-related trials and observational studies and making the information available as a listing on our website. The primary sources are online study registries, particularly the US-based clinicaltrials.gov.

October 6, 2023
TAG Condemns GSK Actions Surrounding Potential TB Vaccine Revealed by Bombshell ProPublica Report
Statement / Press
TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.

October 4, 2023
TAGline October 2023
TAGline
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.

October 2, 2023
TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline
Statement / Press
TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.

September 27, 2023
TAG Remarks Submitted to United Nation High-Level Meetings (UN HLMs), September 2023
Publication
TAG prepared these remarks to deliver at United Nations High-Level Meetings (UN HLMs) on tuberculosis (TB), universal health coverage (UHC), and pandemic prevention, preparedness, and response (PPR). While we welcome public reaffirmation of commitments to end TB, we urge member states to take action that goes beyond what’s outlined in…

September 22, 2023
TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR
Statement / Press
TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from…

September 20, 2023
New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN
Statement / Press
As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.

September 19, 2023
At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens
Statement / Press
Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

September 19, 2023
TAG Reaction to the Price of GeneXpert Tests
Statement / Press
Following intense pressure from TB-affected communities and civil society, Danaher’s price reduction of Xpert tests for TB and resistance to rifampicin (MTB/RIF Ultra) from $9.98 to $7.97 is a significant step forward that will help increase access to a lifesaving TB test and support countries to make progress toward closing…

September 19, 2023
Far Off Track: Funding for TB Research, 2018 – 2022
Publication
United Nations High-Level Meeting on TB Policy Note. At the first United Nations High-Level Meeting (HLM) on TB back in 2018, UN member states pledged “to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to 2 billion dollars […] in funding annually for tuberculosis research”…

September 12, 2023
TAG to Honor Leaders of Latino HIV Community, Pediatric Drug-Resistant TB, and Transgender Health at RIAA 2023
Statement / Press
Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV,…

September 5, 2023
HCV Elimination Among People Living with and at Risk of HIV: Challenges and Opportunities
Webinar / Presentation
Following the White House’s recent proposal for a National Hepatitis C Elimination Plan as part of its Fiscal Year 2024 budget request to Congress, and the fact that key populations for HIV are also at high risk of HCV, Treatment Action Group is organizing a webinar that will highlight best…

August 16, 2023
HIV Community Engagement Manager
Treatment Action Group (TAG) seeks a dynamic, motivated, and skilled individual to become its HIV community engagement manager, supporting the organization as it continues to grow. This position will report to TAG’s HIV project director, and is a full-time, salaried role.

August 16, 2023
Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%
Publication
In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.

August 10, 2023
Letter to Dr. Jeanne Marazzo, New Director NIAID
Letter / Comment
We’re excited to welcome Dr. Jeanne Marazzo as the first woman and openly LGBTQ+ Director of the National Institute of Allergy and Infectious Diseases (NIAID).

August 8, 2023
TAG Mourns the Loss of Dr. Stephaun Elite Wallace
Statement / Press
TAG extends our deepest condolences to the family, friends and loved ones of Dr. Stephaun Elite Wallace, PhD, MS. Dr. Wallace was a treasure to all who knew and worked with him, and his legacy of mentorship and community engagement in the HIV research landscape will be felt for generations.

August 2, 2023
TAG Welcomes Addition of Ravidasvir to WHO Essential Medicines List for Treatment of Hepatitis C Virus
Statement / Press
Treatment Action Group welcomes the inclusion of Ravidasvir on the World Health Organization (WHO) Essential Medicines List (EML) as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection in adults.

August 1, 2023
Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply
Letter / Comment
TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.

July 20, 2023
2023 Pipeline Report
Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).